Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/4/2009

these identifying words. In particular, any statements regarding potential FDA marketing approval for KRYSTEXXA(TM) (pegloticase), whether any further clinical trials will be required, the actions that may be required of Savient by the FDA in connection with the BLA, the reversion to and revalidation of the Phase 3 manufacturing process, the timing of a resubmission to the FDA in response to the complete response letter and the efficacy and safety of KRYSTEXXA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data, our current understanding of the complete response letter and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA or require that we conduct additional clinical trials, our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans,
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... /PRNewswire-iReach/ -- Full Service CRO WCCT Global ... President of Business Development. Peter has been in the ... of different business development positions with some of the ... related to business development/sales management and marketing.  The experience ... him a key and strategic asset to WCCT Global ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, ... Tobago Ministry of Health approved the introduction of ... increases the cure rate from Hepatitis C, and ... genotype 1 virus. Telaprevir is available in ... INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... , July 25, 2014  Solanbridge Group Inc ... acquired the majority interest in Buzznbrewz.com and the Letter ... replaced with a fully executed Purchase Agreement. ... stated "We are proud to have Mr. David ... decades of experience in the private sector and developed ...
Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... , , CHARLOTTESVILLE, Virginia, December ... the 2009 Top Innovator Presentation Award,in Healthcare, at the ... Dedham, MA. The award, which recognizes cutting edge private ... who competed with,over 50 other privately held companies that ...
... , ... CVS/pharmacy and MinuteClinic health care centers located in select ... and Washington, D.C. While in some locations priority restrictions ... allowing all patients to be eligible to receive the shot ...
Cached Medicine Technology:Biovista Inc. Named Top Innovator in Life Sciences 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4
(Date:7/28/2014)... (PRWEB) July 28, 2014 Termed by ... drug abuse causes more fatal overdoses than heroin and ... year. (1) Those who are particularly vulnerable to succumbing ... and up), with many in this age group taking ... this growing epidemic was reawakened in the White House ...
(Date:7/28/2014)... Freeonlinelifeinsuranceleads.com has released a new blog ... insurance quotes. , Comparing life insurance quotes can help ... costs. Finding affordable coverage is easier online by visiting ... agencies and displays them on a single web page. ... find cheaper coverage, but they can also learn more ...
(Date:7/28/2014)... HealthDay Reporter FRIDAY, July 25, 2014 (HealthDay News) ... blood donations from gay and bisexual men, according to a team ... Journal of the American Medical Association . Currently, a man ... in the United States -- a lifetime ban that has been ... adopted this policy at the dawn of the AIDS crisis. ...
(Date:7/28/2014)... By Dennis Thompson ... -- The U.S. Supreme Court,s ruling on contraception coverage -- ... to a legal quagmire that might allow companies to deny ... principles, some health care experts say. But other experts ... The justices ruled 5-4 last month that Hobby Lobby Stores ...
(Date:7/28/2014)... July 28, 2014 For those with dust ... cause of dust allergies—commonly settle in mattresses, bedding, and upholstered ... , Dust mites are microscopic insects that feed on the ... each day to keep a million dust mites fat and ... high power microscope, the decaying bodies and feces of dust ...
Breaking Medicine News(10 mins):Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 2Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 3Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 4Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:Lift U.S. Ban on Blood Donations by Gay Men, Experts Say 2Health News:Lift U.S. Ban on Blood Donations by Gay Men, Experts Say 3Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 2Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 3Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 4Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 5Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 2Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 3
... Present Clinical Data at, ... Upcoming Scientific Meeting -,LAVAL, QC, May ... ) today announced the publication of Extended Release Trazodone in Major ... issue of the journal Psychiatry (Edgemont) (Volume 6, Number 5) ( ...
... German . , When cells cannot carry out ... is disease. Nanobiotechnology researchers are looking for ways to allow ... absent from the cell. This requires transport systems that can ... controlled fashion at the right moment. The transporter must be ...
... Pharmaceutical Research and Manufacturers of America (PhRMA) unveiled a ... for diabetes. The report shows that America,s pharmaceutical research ... diabetes medicines. The medicines listed in the report are ... approval by the U.S. Food and Drug Administration.The report ...
... delivery and glucose sensing leadership INDIANAPOLIS and MINNEAPOLIS, May ... diabetes management -Eli Lilly and Company (NYSE: ... ) - today announced a strategic marketing collaboration to ... manage their blood sugar using insulin therapy.Working collaboratively with ...
... Leading Veterinary Care Digital Imaging and Data Management ... 19 Eklin Medical Systems, a leading provider ... and Communications Systems) and practice management software (VIA(R)) ... Juan Thorn as the company,s West Coast ultrasound ...
... ,sings, could improve our understanding of conditions such as ... at Cardiff University have discovered. , Research by ... Centre (CUBRIC) has discovered that a person,s brain produces ... a person looks at a visual pattern. , ...
Cached Medicine News:Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 2Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 3Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 4Health News:Capsules encapsulated 2Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 2Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 3Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 4Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 2Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 3Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 4Health News:Eklin Medical Systems Appoints Juan Thorn as West Coast Ultrasound Sales Representative 2Health News:'Singing brains' offers epilepsy and schizophrenia clues 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: